Search
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.
Celecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigational[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. … [A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalPancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] … [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms.
Ceftaroline fosamil
go.drugbank.com/drugs/DB06590ApprovedInvestigationalCeftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections
Calcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedBy FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings … It is also present in dental or oral hygiene products due to its cariostatic effects.
Zolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalZolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. … This drug has the propensity to completely or partially reverse the abnormal metabolism of damaged brain cells after injury [L5584], [A175444].
Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamideAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … by the U.S.
Miglitol
go.drugbank.com/drugs/DB00491ApprovedUnlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. … monosaccharides which can be absorbed by the body.
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideProducts: R O Z LytrekGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … [A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip
Synonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea